Equities Analysts Set Expectations for FBRX Q2 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Brookline Capital Markets issued their Q2 2026 earnings per share (EPS) estimates for Forte Biosciences in a research report issued to clients and investors on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($1.08) per share for the quarter. The consensus estimate for Forte Biosciences’ current full-year earnings is ($4.57) per share. Brookline Capital Markets also issued estimates for Forte Biosciences’ Q3 2026 earnings at ($0.90) EPS, FY2026 earnings at ($4.06) EPS, FY2027 earnings at ($2.89) EPS, FY2028 earnings at ($2.61) EPS, FY2029 earnings at ($7.21) EPS and FY2030 earnings at ($5.59) EPS.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Forte Biosciences in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Forte Biosciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 10th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Forte Biosciences Price Performance

NASDAQ:FBRX opened at $23.96 on Friday. The firm’s 50-day moving average price is $27.71 and its 200-day moving average price is $25.52. The company has a market capitalization of $332.80 million, a PE ratio of -5.16 and a beta of 3.01. Forte Biosciences has a 1-year low of $7.00 and a 1-year high of $35.80.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.08).

Institutional Investors Weigh In On Forte Biosciences

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Forte Biosciences by 6.7% in the 2nd quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock worth $829,000 after purchasing an additional 4,028 shares during the last quarter. Orbimed Advisors LLC grew its position in Forte Biosciences by 101.8% during the 2nd quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock valued at $15,477,000 after purchasing an additional 603,867 shares during the last quarter. Cable Car Capital LP increased its stake in Forte Biosciences by 127.7% during the 2nd quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock valued at $6,465,000 after purchasing an additional 280,396 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Forte Biosciences during the 2nd quarter valued at about $4,310,000. Finally, Mink Brook Asset Management LLC purchased a new position in Forte Biosciences in the second quarter worth about $503,000. 77.63% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Forte Biosciences

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Forte Biosciences to ($4.06) from ($4.44), suggesting a slightly better outlook for the current year.
• Positive Sentiment: The firm also improved longer-term earnings estimates, including FY2027 to ($2.89) from ($3.26), FY2028 to ($2.61) from ($2.92), FY2029 to ($7.21) from ($7.49), and FY2030 to ($5.59) from ($6.07), which may signal growing confidence in the company’s future profitability.
• Neutral Sentiment: Brookline also issued fresh quarterly estimates, including Q2 2026 EPS of ($1.08) and Q3 2026 EPS of ($0.90), underscoring that the company is still expected to post losses in the near term.
• Neutral Sentiment: The company is scheduled to release quarterly earnings soon, which likely adds uncertainty and keeps traders focused on the stock. Article Title
• Positive Sentiment: Unusually large options activity showed strong speculation ahead of the report, with investors buying 30,205 call options, far above the normal daily volume. This can sometimes reflect bullish sentiment.
• Negative Sentiment: Despite the upgrades, Forte Biosciences is still expected to report substantial losses, and the company recently missed quarterly EPS expectations, which may weigh on the shares.

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.